The Role of Spinal Dopaminergic Transmission in the Analgesic Effect of Nefopam on Rat Inflammatory Pain
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Nefopam has been known as an inhibitor of the reuptake of monoamines, and the noradrenergic and/or serotonergic system has been focused on as a mechanism of its analgesic action. Here we investigated the role of the spinal dopaminergic neurotransmission in the antinociceptive effect of nefopam administered intravenously or intrathecally.Methods: The effects of intravenously and intrathecally administered nefopam were examined using the rat formalin test. Then we performed a microdialysis study to confirm the change of extracellular dopamine concentration in the spinal dorsal horn by nefopam. To determine whether the changes of dopamine level are associated with the nefopam analgesia, its mechanism was investigated pharmacologically via pretreatment with sulpiride, a dopaminergic D2 receptor antagonist. Results: When nefopam was administered intravenously the flinching responses in phase I of the formalin test were decreased, but not those in phase II of the formalin test were decreased. Intrathecally injected nefopam reduced the flinching responses in both phases of the formalin test in a dose dependent manner. Microdialysis study revealed a significant increase of the level of dopamine in the spinal cord by intrathecally administered nefopam (about 3.8 fold the baseline value) but not by that administered intravenously. The analgesic effects of intrathecally injected nefopam were not affected by pretreatment with sulpiride, and neither were those of the intravenous nefopam.Conclusions: Both the intravenously and intrathecally administered nefopam effectively relieved inflammatory pain in rats. Nefopam may act as an inhibitor of dopamine reuptake when delivered into the spinal cord. However, the analgesic mechanism of nefopam may not involve the dopaminergic transmission at the spinal level. (Korean J Pain 2016; 29: 164-71)
Abstract
Background: Nefopam has been known as an inhibitor of the reuptake of monoamines, and the noradrenergic and/or serotonergic system has been focused on as a mechanism of its analgesic action. Here we investigated the role of the spinal dopaminergic neurotransmission in the antinociceptive effect of nefopam administered intravenously or intrathecally.Methods: The effects of intravenously and intrathecally administered nefopam were examined using the rat formalin test. Then we performed a microdialysis study to confirm the change of extracellular dopamine concentration in the spinal dorsal horn by nefopam. To determine whether the changes of dopamine level are associated with the nefopam analgesia, its mechanism was investigated pharmacologically via pretreatment with sulpiride, a dopaminergic D2 receptor antagonist. Results: When nefopam was administered intravenously the flinching responses in phase I of the formalin test were decreased, but not those in phase II of the formalin test were decreased. Intrathecally injected nefopam reduced the flinching responses in both phases of the formalin test in a dose dependent manner. Microdialysis study revealed a significant increase of the level of dopamine in the spinal cord by intrathecally administered nefopam (about 3.8 fold the baseline value) but not by that administered intravenously. The analgesic effects of intrathecally injected nefopam were not affected by pretreatment with sulpiride, and neither were those of the intravenous nefopam.Conclusions: Both the intravenously and intrathecally administered nefopam effectively relieved inflammatory pain in rats. Nefopam may act as an inhibitor of dopamine reuptake when delivered into the spinal cord. However, the analgesic mechanism of nefopam may not involve the dopaminergic transmission at the spinal level. (Korean J Pain 2016; 29: 164-71)
참고문헌 (24)
- 김경훈, "Rediscovery of Nefopam for the Treatment of Neuropathic Pain", The Korean Journal of Pain, 27(2), pp.103~111 (2014), 대한통증학회
- Esposito E, "Evidence of the involvement of dopamine in the analgesic effect of nefopam", Eur J Pharmacol, 128, pp.157~164 (1986)
- Fuller RW, "Evaluation of nefopam as a monoamine uptake inhibitor in vivo in mice", Neuropharmacology, 32, pp.995~999 (1993)
- Hunskaar S, "Involvement of central serotonergic pathways in nefopam-induced antinociception", Eur J Pharmacol, 138, pp.77~82 (1987)
- Rosland JH, "The effect of nefopam and its enantiomers on the uptake of 5-hydroxytryptamine, noradrenaline and dopamine in crude rat brain synaptosomal preparations", J Pharm Pharmacol, 42, pp.437~438 (1990)
- Vonvoigtlander PF, "Involvement of biogenic amines with the mechanisms of novel analgesics", Prog Neuropsychopharmacol Biol Psychiatry, 7, pp.651~656 (1983)
- Gray AM, "The involvement of opioidergic and noradrenergic mechanisms in nefopam antinociception", Eur J Pharmacol, 365, pp.149~157 (1999)
- Girard P, "Role of catecholamines and serotonin receptor subtypes in nefopam-induced antinociception", Pharmacol Res, 54, pp.195~202 (2006)
- 정신호, "Spinal Noradrenergic Modulation and the Role of the Alpha-2 Receptor in the Antinociceptive Effect of Intrathecal Nefopam in the Formalin Test", The Korean Journal of Pain, 27(1), pp.23~29 (2014), 대한통증학회
- Yaksh TL, "Chronic catheterization of the spinal subarachnoid space", Physiol Behav, 17, pp.1031~1036 (1976)
- 조수영, "Antinociceptive Effect of Intrathecal Nefopam and Interaction with Morphine in Formalin-Induced Pain of Rats", The Korean Journal of Pain, 26(1), pp.14~20 (2013), 대한통증학회
- Coderre TJ, "The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury", J Neurosci, 12, pp.3665~3670 (1992)
- Lee HG, "The antiallodynic effect of intrathecal tianeptine is exerted by increased serotonin and norepinephrine in the spinal dorsal horn", Neurosci Lett, 583, pp.103~107 (2014)
- "Nefopam as a potential PET tracer of serotonin reuptake sites"
- Millan MJ, "Descending control of pain", Prog Neurobiol, 66, pp.355~474 (2002)
- Potvin S, "Human evidence of a supra-spinal modulating role of dopamine on pain perception", Synapse, 63, pp.390~402 (2009)
- Franklin KB, "Analgesia and abuse potential: an accidental association or a common substrate?", Pharmacol Biochem Behav, 59, pp.993~1002 (1998)
- Altier N, "The role of dopamine in the nucleus accumbens in analgesia", Life Sci, 65, pp.2269~2287 (1999)
- Cobacho N, "Dopaminergic modulation of neuropathic pain : analgesia in rats by a D2-type receptor agonist", Brain Res Bull, 106, pp.62~71 (2014)
- Fairbanks CA, "Spinal delivery of analgesics in experimental models of pain and analgesia", Adv Drug Deliv Rev, 55, pp.1007~1041 (2003)
- Xu JJ, "Intermittent lumbar puncture in rats : a novel method for the experimental study of opioid tolerance", Anesth Analg, 103, pp.714~720 (2006)
- Ohkubo Y, "Involvement of dopamine in the mechanism of action of FR64822, a novel non-opioid antinociceptive compound", Eur J Pharmacol, 204, pp.121~125 (1991)
- Novelli A, "Nefopam inhibits calcium influx, cGMP formation, and NMDA receptor-dependent neurotoxicity following activation of voltage sensitive calcium channels", Amino Acids, 28, pp.183~191 (2005)
- Verleye M, "Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents", Brain Res, 1013, pp.249~255 (2004)